Agios Pharmaceuticals Inc. (NASDAQ:AGIO) stock plunged on Wednesday after the company released topline results from RISE UP Phase 3 data for mitapivat in sickle cell disease.AGIO is testing key support levels. See what the experts say hereThe trial met its primary endpoint of hemoglobin response, with mitapivat demonstrating a statistically significant improvement compared to placebo.Also Read: FDA Delays Decision On Agios Pharmaceuticals’ Blood Disorder Drug For Expanded UseDataWhile mitapivat also showed ...